Fosmanogepix (DB15183): A Comprehensive Monograph on a First-in-Class Investigational Antifungal Agent

Executive Summary

Fosmanogepix is an investigational, first-in-class antifungal agent that represents a potentially transformative advancement in the treatment of invasive fungal infections (IFIs). As a water-soluble N-phosphonooxymethylene prodrug, fosmanogepix is rapidly and completely converted in vivo to its active moiety, manogepix. The therapeutic action of manogepix is derived from a novel mechanism: the specific inhibition of the fungal enzyme Gwt1 (Glycosylphosphatidylinositol-anchored Wall protein Transfer 1). This enzyme is essential for an early step in the biosynthesis of GPI anchors, which are required to attach critical mannoproteins to the fungal cell wall. By disrupting this pathway, manogepix compromises fungal cell wall integrity, inhibits virulence factors such as hyphal and biofilm formation, and ultimately leads to fungal cell death.

The clinical promise of fosmanogepix is underscored by its broad spectrum of activity. In vitro and in vivo studies have demonstrated potent activity against a wide array of clinically significant yeasts and molds. This includes common pathogens such as Candida and Aspergillus species, as well as difficult-to-treat, multidrug-resistant organisms like Candida auris, echinocandin-resistant Candida, and azole-resistant Aspergillus. Furthermore, it has shown activity against rare molds that are often intrinsically resistant to standard therapies, including species of Fusarium, Scedosporium, and Lomentospora prolificans.

Pharmacologically, fosmanogepix exhibits a highly favorable profile. It is available in both intravenous (IV) and oral formulations, with the oral form demonstrating excellent bioavailability exceeding 90%. This characteristic facilitates a seamless transition from IV to oral therapy, potentially enabling earlier hospital discharge and simplifying long-term treatment. Manogepix has a long elimination half-life of approximately two days and achieves wide tissue distribution, including penetration into sanctuary sites such as the central nervous system (CNS) and the eye—a critical advantage over existing antifungal classes like the echinocandins.

Clinical data from Phase 1 and 2 trials have established a favorable safety and tolerability profile, with the most common adverse events being mild-to-moderate gastrointestinal effects. Notably, the drug has not been associated with the significant nephrotoxicity or hepatotoxicity that limits the use of other major antifungal classes. Recognizing its potential to address a significant unmet medical need, regulatory agencies have granted fosmanogepix multiple expedited pathway designations, including Fast Track, Qualified Infectious Disease Product (QIDP), and Orphan Drug status in the United States and Europe. Having demonstrated proof-of-concept in Phase 2 studies, fosmanogepix is now advancing into pivotal Phase 3 registrational trials for the treatment of candidemia/invasive candidiasis and invasive mold infections, positioning it as a critical new therapeutic option in the global fight against life-threatening fungal diseases.

Introduction: The Evolving Landscape of Invasive Fungal Infections and the Need for Novel Therapeutics

The Unmet Medical Need

Invasive fungal infections (IFIs) have emerged as a growing and formidable threat to global public health, representing a significant cause of morbidity and mortality, particularly among immunocompromised and critically ill patient populations.[1] The incidence of these life-threatening infections has risen substantially due to the expansion of modern medical interventions, such as solid-organ and hematopoietic stem cell transplantation, aggressive cancer chemotherapy regimens, and the widespread use of immunosuppressive therapies.[1] The clinical consequences of IFIs are severe, with mortality rates remaining unacceptably high despite the availability of antifungal treatments. For instance, mortality estimates range from 46-75% for candidiasis, 30-95% for aspergillosis, and 30-90% for infections caused by rare molds.[2] The global burden is substantial, with estimates exceeding two million life-threatening infections annually.[7] This clinical challenge is compounded by diagnostic delays, which often prevent the early initiation of appropriate therapy, a key determinant of patient outcomes.[1]

Limitations of the Current Antifungal Armamentarium

The therapeutic options for treating IFIs are currently limited to a few major drug classes, each with significant liabilities that create a pressing unmet medical need for safer, more effective, and more versatile agents.[8]

• Polyenes: The polyene class, primarily represented by amphotericin B, offers a broad spectrum of activity but is severely limited by its toxicity profile. Significant nephrotoxicity is a common and dose-limiting adverse effect, complicating its use in critically ill patients who often have pre-existing renal dysfunction.[5] Furthermore, polyenes are only available in intravenous (IV) formulations, precluding oral step-down therapy and necessitating prolonged hospitalization.
• Azoles: The azole antifungals (e.g., fluconazole, voriconazole) are widely used due to their broad spectrum and availability in both IV and oral formulations. However, their clinical utility is increasingly compromised by the rapid emergence of acquired fungal resistance.[8] Their use is also complicated by a propensity for significant drug-drug interactions (DDIs) via inhibition of cytochrome P450 enzymes, the potential for liver toxicity, and erratic pharmacokinetics that can lead to therapeutic failures or toxicity.[5]
• Echinocandins: This class (e.g., caspofungin, micafungin) has become a first-line therapy for invasive candidiasis due to its excellent safety profile and potent activity against most Candida species.[8] However, the echinocandins have three major limitations: their spectrum of activity against molds is variable; they are only available as IV formulations, limiting their use outside the hospital setting; and they exhibit poor penetration into sanctuary sites such as the central nervous system (CNS) and the eye, making them unsuitable for treating fungal meningitis or endophthalmitis.[8]

Introducing Fosmanogepix

In response to these challenges, fosmanogepix (formerly APX001) has been developed as a first-in-class investigational agent belonging to the novel "gepix" class of antifungals.[9] It is a prodrug of the active moiety, manogepix, and was specifically designed to overcome the deficiencies of existing therapies. Its unique mechanism of action, targeting the fungal-specific enzyme Gwt1, provides a basis for its broad-spectrum activity, including against pathogens resistant to other drug classes.[10] Combined with a pharmacological profile that includes both IV and highly bioavailable oral formulations and demonstrated penetration into the CNS, fosmanogepix represents a critical innovation aimed at addressing the most pressing unmet needs in the management of invasive fungal infections.[1]

Molecular Profile and Physicochemical Characteristics

Comprehensive Identification

A definitive molecular and chemical identity is established for fosmanogepix through a comprehensive set of standardized identifiers. This ensures precise communication and information retrieval across scientific databases and regulatory documents.

• Generic Name: Fosmanogepix.[16]
• Synonyms and Developmental Codes: The compound has been known by several codes throughout its development, including APX001, APX-001, PF-07842805, and E1211.[1]
• DrugBank ID: DB15183.[16]
• CAS Number: 2091769-17-2.[16]

Structural and Chemical Data

Fosmanogepix is classified as a small molecule drug, defined by the following structural and chemical properties:

• Type: Small Molecule.[17]
• Chemical Formula: C22​H21​N4​O6​P.[16]
• Molecular Weight / Molar Mass: The average molecular weight is 468.406 g·mol⁻¹, with values often rounded to 468.41 g·mol⁻¹ in technical literature.[16] The monoisotopic mass is 468.11987141 Da.[17]
• IUPAC Name: The systematic name for the compound is [2-Amino-3-(3-{4-[(2-pyridinyloxy)methyl]benzyl}-1,2-oxazol-5-yl)-1-pyridiniumyl]methyl hydrogen phosphate.[16] An alternative name, ({2-imino-3-[3-({4-[(pyridin-2-yloxy)methyl]phenyl}methyl)-1,2-oxazol-5-yl]-1,2-dihydropyridin-1-yl}methoxy)phosphonic acid, has also been reported.[22]
• SMILES (Simplified Molecular-Input Line-Entry System): c1ccnc(c1)OCc2ccc(cc2)Cc3cc(on3)c4ccc[n+](c4N)COP(=O)(O)[O-].[16]
• InChI Key (International Chemical Identifier Key): JQONJQKKVAHONF-UHFFFAOYSA-N.[16]

Physicochemical Properties

The physicochemical properties of fosmanogepix dictate its behavior in biological systems and are fundamental to its formulation development and pharmacokinetic profile. The low aqueous solubility, for example, is a key reason for its development as a phosphate prodrug, which enhances solubility for intravenous formulation. Key computed properties are summarized in Table 1.

Table 1: Physicochemical Properties of Fosmanogepix

Property	Value	Source
Water Solubility	0.0209 mg/mL	ALOGPS
logP (Octanol-Water Partition Coefficient)	1.13	ALOGPS
logS (Aqueous Solubility)	-4.4	ALOGPS
pKa (Strongest Acidic)	0.44	Chemaxon
pKa (Strongest Basic)	3.87	Chemaxon
Physiological Charge (at pH 7.4)	-1	Chemaxon
Hydrogen Acceptor Count	7	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	147.64 A˚2	Chemaxon
Rotatable Bond Count	9	Chemaxon
Rule of Five Compliance	Yes	Chemaxon
Data sourced from DrugBank.17

Developmental History and Regulatory Pathway

Corporate Stewardship and Strategic Rationale

The development of fosmanogepix has followed a strategic trajectory involving specialized biotechnology and major pharmaceutical companies, reflecting a process of progressive validation and de-risking of the asset.

1. Initial Development by Amplyx Pharmaceuticals: Fosmanogepix (as APX001) was originally developed as the lead antifungal candidate by Amplyx Pharmaceuticals, a biotechnology company focused on therapies for immunocompromised patients.[10]
2. Acquisition by Pfizer: In April 2021, following a prior equity investment in 2019, Pfizer Inc. acquired Amplyx Pharmaceuticals. This acquisition was a significant validation of the preclinical and early clinical data for fosmanogepix, incorporating the novel antifungal into the robust anti-infectives pipeline of a major pharmaceutical organization and substantially de-risking its future development.[14]
3. Acquisition by Basilea Pharmaceutica: In a strategic move in November 2023, Basilea Pharmaceutica Ltd., a Swiss biopharmaceutical company with a dedicated focus on hospital anti-infectives, acquired the global rights for fosmanogepix from Pfizer's affiliate, Amplyx.[27] This transaction placed the late-stage asset with a company possessing specialized expertise in the clinical development and commercialization of novel hospital-based anti-infectives. Under the terms of the agreement, Pfizer retains a right of first negotiation for commercial rights upon successful completion of the Phase 3 program, indicating continued strategic interest in the asset's success.[28]

This developmental path is not indicative of a failing asset but rather a strategic handover. The initial development by a focused biotech, subsequent validation and resourcing by a large pharmaceutical company, and final transfer to a specialized late-stage development and commercialization partner represents a logical and efficient progression for a novel hospital-based therapeutic. It suggests the drug has successfully cleared critical early- and mid-stage hurdles and is now on a clear trajectory toward registration and market launch.

Regulatory Milestones and Expedited Pathways

The significant unmet medical need for novel antifungals is reflected in the multiple special designations and expedited pathway opportunities granted to fosmanogepix by regulatory authorities in the United States and Europe.

• U.S. Food and Drug Administration (FDA):
• Qualified Infectious Disease Product (QIDP): Fosmanogepix has been granted QIDP designation for the treatment of infections caused by four major fungal pathogens: Candida species, Aspergillus species, Coccidioides species, and Cryptococcus species. This designation makes the drug eligible for priority review and provides an additional five years of U.S. market exclusivity if approved.[24]
• Fast Track Designation: Both the IV and oral formulations have received Fast Track designation for seven separate indications: invasive candidiasis, invasive aspergillosis, scedosporiosis, fusariosis, mucormycosis, cryptococcosis, and coccidioidomycosis. This status is intended to facilitate and expedite the development and review process for drugs that treat serious conditions and fill an unmet medical need.[24]
• Orphan Drug Designation (ODD): The FDA has granted ODD for multiple indications, including the treatment of invasive candidiasis (designated on October 19, 2016), invasive aspergillosis, cryptococcosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp., and Mucorales fungi. ODD provides development incentives and seven years of market exclusivity for the designated indication upon approval.[24]
• European Medicines Agency (EMA):
• Orphan Designation: On July 18, 2022, the EMA granted fosmanogepix orphan medicinal product designation (EU/3/22/2644) for the treatment of invasive candidiasis. This provides access to scientific and regulatory support from the EMA and potential market exclusivity in the EU upon authorization.[34]
• Compassionate Use and Expanded Access: Highlighting its potential in dire clinical situations, fosmanogepix was granted compassionate use authorization in 2023 for four patients with iatrogenic Fusarium solani meningitis.[16] Furthermore, an Expanded Access Program (EAP) (NCT06433128) has been established by Basilea to provide the drug to patients aged 12 and older with serious or life-threatening IFIs who have no other treatment options.[35]

The combination of these regulatory designations creates a powerful commercial and developmental incentive structure. The designations are not merely redundant accolades; they serve distinct purposes. Fast Track accelerates the timeline to potential approval. QIDP and ODD, meanwhile, provide overlapping but combinable periods of market protection. As noted in regulatory analyses, these designations can provide a total of up to twelve years of marketing exclusivity in the U.S..[24] This robust exclusivity is a critical commercial driver that helps justify the substantial financial investment required to conduct two large, global Phase 3 registrational trials, a particularly important consideration in the economically challenging field of anti-infective development.

Preclinical Pharmacology

A. Mechanism of Action: A First-in-Class Approach

The antifungal activity of fosmanogepix is rooted in a novel mechanism of action that is distinct from all currently approved systemic antifungal agents.

Prodrug Activation

Fosmanogepix itself is not the active antifungal agent. It is a water-soluble N-phosphonooxymethylene prodrug, a chemical structure designed to improve the compound's pharmaceutical properties, particularly solubility for intravenous administration.[1] Following administration, fosmanogepix undergoes rapid and complete metabolism

in vivo by ubiquitous systemic alkaline phosphatases. This enzymatic cleavage releases the active moiety, manogepix (also known as MGX, APX001A, or E1210).[1]

Molecular Target and Biochemical Pathway Disruption

Manogepix exerts its fungicidal effect by specifically inhibiting the fungal enzyme Gwt1, which stands for Glycosylphosphatidylinositol-anchored Wall protein Transfer 1.[9] Gwt1 is a highly conserved and essential enzyme located in the endoplasmic reticulum of fungal cells. It plays a critical role in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors—complex glycolipids that are used to attach a wide variety of proteins to the cell surface. Specifically, Gwt1 catalyzes the inositol acylation of an early intermediate in the pathway, glucosaminyl-phosphatidylinositol (GlcN-PI).[1]

Downstream Cellular Effects

By blocking this essential enzymatic step, manogepix prevents the proper maturation and trafficking of GPI-anchored proteins. These proteins are vital for numerous aspects of fungal physiology and virulence. The consequences of Gwt1 inhibition are pleiotropic and catastrophic for the fungal cell, leading to:

• Compromised Cell Wall Integrity: The inability to properly anchor key mannoproteins to the cell wall weakens its structural integrity, making the fungus susceptible to osmotic stress and cell lysis.[1]
• Inhibition of Virulence Factors: The disruption of GPI-anchored protein localization inhibits critical virulence processes such as the formation of hyphae and germ tubes (essential for tissue invasion by yeasts like Candida) and the formation of biofilms (a key mechanism of drug resistance and persistence).[15]
• Cellular Defects and Death: The cumulative effect of these disruptions leads to severe growth defects, malformation of cell size and shape, and ultimately, fungal cell death.[1]

A key attribute that underpins the favorable safety profile of fosmanogepix is the high degree of specificity of its active moiety for the fungal target. The development of safe and effective antifungals is challenging due to the eukaryotic nature of both fungal and human cells. A successful drug must exploit pathways that are unique to the pathogen. The Gwt1 pathway provides such a target. Extensive research has demonstrated that manogepix is highly selective for the fungal Gwt1 enzyme and exhibits no inhibitory activity against its closest human ortholog, the phosphatidylinositol glycan anchor biosynthesis class W (PIG-W) protein.[9] This molecular specificity creates a significant "target-based safety therapeutic window," directly explaining the lack of systemic organ toxicities, such as the nephrotoxicity seen with amphotericin B or the hepatotoxicity associated with azoles, that has been observed throughout the clinical development program.

Furthermore, this entirely novel mechanism of action provides an inherent advantage in overcoming existing patterns of antifungal resistance. Clinical resistance to azoles, which target ergosterol synthesis, and echinocandins, which target glucan synthesis, is a growing global health crisis. Because manogepix acts on a completely independent biochemical pathway, fungal isolates that have developed resistance to azoles or echinocandins via mutations in their respective target enzymes remain fully susceptible to manogepix. This is explicitly supported by preclinical data showing potent activity against echinocandin-resistant Candida and azole-resistant Aspergillus strains.[1] This positions fosmanogepix not merely as another therapeutic option, but as a potential breakthrough for treating infections caused by multidrug-resistant pathogens for which few or no effective treatments exist.

B. Pharmacodynamics: Spectrum of Antimicrobial Activity

The pharmacodynamic profile of manogepix is characterized by potent, broad-spectrum activity against a wide range of clinically important fungal pathogens, confirmed through extensive in vitro susceptibility testing and in vivo animal models of infection.

In Vitro Susceptibility

Manogepix has demonstrated potent in vitro activity against a diverse collection of yeasts and molds, including many strains resistant to current standard-of-care agents. For molds, activity is often measured by the Minimum Effective Concentration (MEC), the lowest drug concentration that leads to the growth of abnormal, compact hyphae, while for yeasts, the Minimum Inhibitory Concentration (MIC), the lowest concentration that inhibits visible growth, is used.

• Yeasts: Manogepix is highly active against most clinically relevant Candida species, including C. albicans, C. glabrata, and C. tropicalis. Of particular importance is its potent activity against the emerging multidrug-resistant pathogen Candida auris, for which therapeutic options are severely limited.[1] It is also active against Cryptococcus neoformans and C. gattii, the causative agents of cryptococcosis.[9] An important exception is its poor in vitro activity against Candida krusei.[14]
• Molds: The drug shows potent activity against common pathogenic molds, including Aspergillus fumigatus and Aspergillus flavus.[6] A key strength is its activity against a variety of rare and difficult-to-treat molds that exhibit intrinsic resistance to many other antifungal classes. This includes species of Scedosporium, Lomentospora prolificans, and Fusarium.[1]
• Mucorales: The activity of manogepix against fungi of the order Mucorales, the agents of mucormycosis, has been described as variable.[1]

The clinical relevance of this potency is best understood by comparing its activity to that of established antifungals, as summarized in Table 2.

Table 2: Summary of In Vitro Activity of Manogepix Against Key Fungal Pathogens

Fungal Species/Group	Manogepix MIC₅₀/MEC₅₀ (mg/L)	Manogepix MIC₉₀/MEC₉₀ (mg/L)	Representative Comparator MIC₉₀ (mg/L)
Candida spp. (aggregate)	0.008	0.06	Fluconazole: >64; Caspofungin: 0.25
Candida auris	0.004 - 0.03	0.015 - 0.03	Fluconazole: >256; Amphotericin B: 2
Cryptococcus neoformans	0.5	1	Fluconazole: 8; Amphotericin B: 0.5
Aspergillus fumigatus	MEC: 0.015	MEC: 0.03	Voriconazole: 0.5; Itraconazole: 1
Scedosporium spp.	MEC: 0.06	MEC: 0.12	Voriconazole: 1
Fusarium spp.	MEC: ≤0.015	MEC: 0.12	Amphotericin B: 2; Voriconazole: 8
Data compiled from multiple international surveillance studies and reports.39 MIC/MEC values can vary by testing methodology (e.g., CLSI vs. EUCAST) and specific species complex.

In Vivo Efficacy

The potent in vitro activity of manogepix translates to robust efficacy in numerous well-established animal models of invasive fungal disease. Treatment with fosmanogepix has consistently resulted in improved survival and a significant reduction in fungal burden in target organs across a range of infections.

• Disseminated Infections: Efficacy has been demonstrated in murine and rabbit models of disseminated candidiasis (caused by C. albicans, C. glabrata, and C. auris), cryptococcosis, coccidioidomycosis, and fusariosis.[1]
• Pulmonary Infections: The drug has shown significant efficacy in pulmonary infection models of aspergillosis (A. fumigatus, A. flavus), scedosporiosis (S. prolificans, S. apiospermum), and mucormycosis (Rhizopus arrhizus).[1]
• Sanctuary Site Infections: Critically, studies have demonstrated significant reductions in the fungal burden within the lung, kidney, eye, spinal cord, and brain, confirming that the drug reaches these difficult-to-penetrate tissues at therapeutic concentrations.[9]

C. Pharmacokinetics (PK): Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of fosmanogepix and its active moiety manogepix is highly favorable and addresses many of the limitations of existing antifungal agents.

• Absorption and Bioavailability: Following oral administration, fosmanogepix is well absorbed. This leads to an excellent oral bioavailability for the active moiety, manogepix, that consistently ranges from 90.6% to 101.2%.[1] This near-complete bioavailability is a key clinical advantage, as it allows for a predictable and reliable transition from intravenous to oral therapy without loss of exposure, facilitating earlier hospital discharge. While food does not significantly affect overall drug exposure ( AUC), administering the oral dose after a meal (post cibum) has been shown to improve gastrointestinal tolerability.[3]
• Distribution: Manogepix exhibits extensive distribution into various tissues throughout the body, a critical feature for treating disseminated infections. Its ability to penetrate sanctuary sites is a major point of differentiation from other antifungal classes.
• Central Nervous System (CNS) Penetration: In rabbit models of hematogenous meningoencephalitis, manogepix demonstrated excellent penetration into the CNS, achieving tissue-to-plasma concentration ratios of approximately 1:1 in the meninges, cerebrum, cerebellum, and spinal cord. This distribution correlated directly with a significant, dose-dependent reduction in fungal burden in these tissues.[36] This property is a stark contrast to the echinocandins, which do not achieve reliable therapeutic concentrations in the CNS.[8]
• Ocular Penetration: In the same rabbit models, manogepix was shown to penetrate into ocular tissues, including the aqueous humor, vitreous, and choroid. The concentrations achieved were sufficient to produce a significant reduction in fungal burden in models of Candida endophthalmitis.[36]
• Metabolism: Fosmanogepix functions as an ideal prodrug. It is rapidly and completely cleaved by systemic alkaline phosphatases to release the active drug, manogepix. The conversion is so efficient that plasma concentrations of the parent prodrug, fosmanogepix, are only transiently detectable for 4-12 hours following an IV infusion and are generally below the limit of quantification after oral administration due to extensive first-pass metabolism in the gut wall and liver.[1]
• Elimination: Manogepix is characterized by a long elimination half-life, which has been consistently measured at approximately 2 days (48 to 60 hours) in studies involving both healthy volunteers and neutropenic patients with acute myeloid leukemia (AML).[3] The pharmacokinetics of manogepix are linear and dose-proportional over a wide range of both IV (10 mg to 1,000 mg) and oral (100 mg to 1,000 mg) doses of fosmanogepix, indicating predictable and consistent exposure with dose adjustments.[3]

The collective pharmacokinetic and pharmacodynamic properties of fosmanogepix are not merely a collection of favorable attributes but are synergistically aligned to create what could be an ideal agent for managing complex, disseminated fungal infections. Effective therapy depends not just on a drug's potency (in vitro activity) but on its ability to reach the site of infection at a sufficient concentration and for a sufficient duration. Fosmanogepix excels in this regard. Its high and reliable oral bioavailability enables a seamless IV-to-oral switch, a cornerstone of modern antimicrobial stewardship that can reduce healthcare costs and risks associated with prolonged IV access. Its long half-life supports a convenient once-daily dosing schedule and ensures sustained drug exposure above target concentrations. Most critically, its demonstrated ability to penetrate the CNS and eye directly addresses a major therapeutic gap left by the echinocandins, the current first-line standard for candidemia. This comprehensive profile suggests that fosmanogepix is uniquely equipped to manage the full clinical course of a severe IFI, from initial, aggressive IV therapy for acute illness to reliable oral step-down therapy for the eradication of deep-seated or sanctuary site infections.

Clinical Development and Efficacy

The clinical development program for fosmanogepix has systematically progressed from foundational safety and pharmacokinetic studies in healthy volunteers to proof-of-concept efficacy trials in patients with life-threatening IFIs, and is now advancing into large-scale registrational Phase 3 studies.

A. Phase 1 Studies

A series of Phase 1 studies established the fundamental clinical pharmacology, safety, and tolerability of fosmanogepix.

• NCT02956499 and NCT02957929: These two key studies evaluated single- and multiple-ascending doses of the intravenous and oral formulations, respectively, in healthy volunteers. The results demonstrated that fosmanogepix was safe and well-tolerated across a wide dose range. They confirmed the linear, dose-proportional pharmacokinetics of the active moiety, manogepix, and established its high oral bioavailability and long half-life. No dose-limiting toxicities were identified.[3]
• Additional Studies: Other completed Phase 1 trials have assessed the mass balance and metabolite profile of the drug (NCT04804059), evaluated potential drug-drug interactions with CYP enzyme inducers and inhibitors (NCT04166669), and established the bioequivalence of different tablet formulations (NCT05491733).[48]

B. Phase 2 Studies: Proof-of-Concept in Patients

Phase 2 trials provided the first evidence of clinical efficacy in patients with active infections, yielding highly promising results that supported advancement to Phase 3.

• Candidemia (NCT03604705): This global, multicenter, open-label, single-arm study served as the primary proof-of-concept trial for fosmanogepix as a first-line treatment for candidemia in 21 non-neutropenic adults. The study met its primary efficacy endpoint, demonstrating a treatment success rate of 80% (16 of 20 patients in the modified intent-to-treat population) as determined by an independent Data Review Committee at the End of Study Treatment (EOST). The Day 30 survival rate was 85% (17 of 20 patients). The drug was well-tolerated, with no treatment-related serious adverse events or discontinuations.[4] A crucial subset analysis of the 14 patients with baseline renal insufficiency showed a similarly high treatment success rate of 86% and, importantly, no evidence of drug-related nephrotoxicity, highlighting a key potential advantage over amphotericin B.[50]
• Candida auris Candidemia (NCT04148287): Recognizing the urgent threat posed by the multidrug-resistant yeast C. auris, a dedicated open-label study was conducted in patients with candidemia or invasive candidiasis caused by this pathogen. In the nine patients who received treatment, fosmanogepix demonstrated an impressive treatment success rate of 89% (8 of 9 patients). This result provided strong clinical validation for the potent in vitro activity observed against this difficult-to-treat organism.[15]
• Invasive Mold Infections (AEGIS study, NCT04240886): This open-label study was designed to evaluate fosmanogepix in patients with invasive mold infections (caused by Aspergillus or rare molds) who had limited treatment options. Although the study was ultimately terminated, data were reported for 21 enrolled patients.[53] In this high-risk population, the safety profile was deemed acceptable. The Day-42 all-cause mortality was 25%, and the Data Review Committee-assessed global response success rate was 40%.[5]

C. Phase 3 Registrational Program: The Path to Approval

Building on the strong Phase 2 data, Basilea Pharmaceutica is now conducting a comprehensive Phase 3 program designed to secure regulatory approval for fosmanogepix in its primary indications. The overall clinical program is summarized in Table 3.

Table 3: Overview of Key Fosmanogepix Clinical Trials

Trial ID (NCT)	Phase	Title / Condition	Status	Key Design / Comparator
NCT02956499	1	Safety, Tolerability and PK of IV APX001	Completed	Placebo-controlled, SAD/MAD
NCT02957929	1	Safety, PK, Bioavailability of Oral APX001	Completed	Placebo-controlled, SAD/MAD
NCT03604705	2	Efficacy and Safety of APX001 in Candidemia	Completed	Open-label, single-arm
NCT04148287	2	APX001 for Treatment of Candida auris	Completed	Open-label, single-arm
NCT04240886	2	APX001 for Treatment of Invasive Mold Infections	Terminated	Open-label, single-arm
NCT05421858	3	FAST-IC: Fosmanogepix for Candidemia/Invasive Candidiasis	Recruiting	Randomized, double-blind vs. Caspofungin/Fluconazole
NCT06925321	3	FORWARD-IM: Fosmanogepix for Invasive Mold Infections	Not yet recruiting	Open-label, randomized vs. Standard of Care
SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; PK: Pharmacokinetics.

FAST-IC Study (NCT05421858): Candidemia and Invasive Candidiasis

This pivotal trial is designed to confirm the efficacy and safety of fosmanogepix for the treatment of invasive Candida infections.

• Status: The study was initiated by Basilea in September 2024 and is currently active and recruiting participants.[27]
• Design: The FAST-IC (Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis) study is a global, multicenter, randomized, active-controlled, double-blind trial. It aims to enroll approximately 450 adult patients.[27]
• Intervention: Patients are randomized in a 2:1 ratio. The experimental arm receives IV fosmanogepix with an option to switch to oral fosmanogepix. The active comparator arm receives a standard-of-care regimen of IV caspofungin with an option to switch to oral fluconazole.[27]
• Primary Outcome: The primary objective is to demonstrate that the fosmanogepix regimen is non-inferior to the standard-of-care regimen. The primary endpoint is the rate of overall success (a composite of clinical cure, mycological eradication, and survival) at Day 42, with a pre-specified non-inferiority margin of 15%.[54]

FORWARD-IM Study (NCT06925321): Invasive Mold Infections

This second Phase 3 study will evaluate fosmanogepix in the treatment of invasive mold infections, a setting with high mortality and limited therapeutic options.

• Status: The study was initiated by Basilea in July 2025 and is listed as active but not yet recruiting participants.[29]
• Design: The FORWARD-IM (FOsmanogepix study Run Worldwide as Antifungal treatment in Resistant Disease caused by Invasive Molds) study is an open-label, two-cohort trial.[29]
• Cohorts: The study includes two distinct patient populations. Cohort A will be a randomized cohort, enrolling approximately 160 patients who will be assigned in a 2:1 ratio to receive either fosmanogepix or a standard-of-care therapy selected by the investigator. Cohort B will be a single-arm salvage therapy cohort, enrolling approximately 60 patients who are intolerant to, or have infections refractory to, standard therapy; all patients in this cohort will receive fosmanogepix.[29]
• Primary Outcome: The specific primary outcome measures for this trial were not detailed in the available documentation.[60]

Clinical Safety and Tolerability

Across the entire clinical development program, from Phase 1 studies in healthy volunteers to Phase 2 studies in critically ill patients, fosmanogepix has consistently demonstrated a favorable safety and tolerability profile.[4]

Adverse Event (AE) Profile

The adverse events associated with fosmanogepix have been predominantly mild to moderate in severity and have not led to significant rates of treatment discontinuation.

• Common Adverse Events: The most frequently reported treatment-related AEs are gastrointestinal in nature, primarily Grade 1 or 2 nausea and vomiting.[11] In clinical trials, the tolerability of the oral formulation was noted to improve when administered with food.[9] Studies exploring higher intravenous doses found that the incidence of nausea and vomiting could be effectively managed with the prophylactic or as-needed use of antiemetics such as ondansetron.[11] Other less frequent drug-related AEs reported in a study of neutropenic AML patients included delirium and transient increases in Alanine Aminotransferase (ALT).[12]
• Serious Adverse Events (SAEs): A key finding from the clinical program is the low incidence of serious adverse events attributed to the study drug. In the pivotal Phase 2 trial for candidemia (NCT03604705), there were no treatment-related SAEs and no patients discontinued the drug due to an adverse event.[4] Similarly, in a Phase 1b study conducted in a fragile population of AML patients with prolonged neutropenia, no SAEs or treatment discontinuations were attributed to fosmanogepix.[12]

Key Safety Parameters

Fosmanogepix appears to lack the signature organ toxicities that plague other major antifungal classes, which could be a major differentiating factor in clinical practice.

• Renal Function: One of the most significant safety findings is the absence of drug-related nephrotoxicity. A dedicated analysis from the Phase 2 candidemia study focused on patients with pre-existing mild, moderate, or severe renal insufficiency. This analysis found no evidence of worsening renal function during treatment and confirmed that no dose adjustments were necessary. The drug was highly efficacious in this population.[50] This favorable renal safety profile presents a stark and highly valuable contrast to the well-documented nephrotoxicity of amphotericin B formulations.
• Hepatic Function: While mild, transient increases in liver enzymes (ALT) have been reported as possibly related to fosmanogepix, the incidence appears low and has not emerged as a significant safety concern.[12] The overall hepatic safety profile appears more favorable than that of the azole class, which is associated with a higher risk of hepatotoxicity and requires routine liver function monitoring.

The collective safety data suggest that fosmanogepix may be one of the best-tolerated systemic antifungal agents developed to date. This favorable profile could be its most important clinical differentiator, particularly for the management of IFIs in complex, fragile patient populations. Patients with IFIs are often critically ill, with multi-organ dysfunction and extensive polypharmacy. In this context, the significant toxicities of standard agents—nephrotoxicity with amphotericin B and hepatotoxicity and DDIs with azoles—can severely complicate treatment, force dose reductions, or lead to discontinuation of life-saving therapy. The clean profile of fosmanogepix with respect to major organ toxicity, combined with preliminary data suggesting a low potential for clinically significant DDIs [38], could allow clinicians to treat severe fungal infections aggressively without the competing concern of exacerbating underlying renal or hepatic disease. This could position fosmanogepix as a preferred agent for high-risk patients, such as those with candidemia and concurrent renal impairment, a very common and challenging clinical scenario.

Synthesis and Future Outlook

Critical Assessment of Therapeutic Potential

Fosmanogepix is poised to become a transformative agent in the clinical management of invasive fungal infections. Its profile is uniquely well-rounded, addressing the most significant and persistent limitations of all three major classes of currently available systemic antifungals. The synthesis of its key attributes—a first-in-class mechanism of action, potent broad-spectrum activity, and a uniquely favorable pharmacokinetic and safety profile—positions it as a landmark advance in antifungal therapy.

The novel Gwt1-inhibiting mechanism provides a powerful tool against the rising tide of antimicrobial resistance, demonstrating potent activity against pathogens that have evolved to evade the mechanisms of azoles and echinocandins. Its broad spectrum of activity covers not only the most common causes of IFIs, Candida and Aspergillus, but also extends to a range of rare and notoriously difficult-to-treat molds, offering new hope for patients with these devastating infections.

Perhaps most compelling is its "best-of-all-worlds" pharmacological profile. It combines the convenience of a highly bioavailable oral formulation, similar to the azoles, with the favorable safety profile characteristic of the echinocandins, while avoiding the major toxicities of both. Crucially, it adds a dimension that no other class fully provides: reliable penetration into sanctuary sites like the CNS and eye, enabling the effective treatment of the most severe and sequestered forms of disseminated fungal disease.

Positioning in Clinical Practice

Upon successful completion of its Phase 3 program and subsequent regulatory approval, fosmanogepix could fundamentally alter treatment paradigms for IFIs.

• For Invasive Candidiasis: If the FAST-IC trial demonstrates non-inferiority to the caspofungin/fluconazole standard of care, fosmanogepix could be positioned as a first-line therapy for candidemia and invasive candidiasis. It would offer a single agent that provides the safety of an echinocandin with the added benefits of a reliable oral switch option and efficacy in CNS and ocular infections. It may become the agent of choice for patients with renal impairment, where avoiding even potentially nephrotoxic agents is a priority.
• For Invasive Mold Infections: In the treatment of invasive aspergillosis and infections caused by rare molds, fosmanogepix is likely to be positioned as a critical second-line or salvage therapy for patients who are intolerant of, or have infections resistant to, standard therapies like voriconazole or amphotericin B. For infections caused by pathogens with intrinsic resistance to azoles, such as Scedosporium or Lomentospora, it could become a first-line option.

Conclusion

Fosmanogepix represents one of the most significant and promising antifungal candidates to reach late-stage clinical development in decades. Its comprehensive and highly differentiated profile—from its molecular mechanism to its clinical safety and efficacy data—directly addresses the most critical unmet needs in the field of medical mycology. It holds the potential to improve outcomes for patients with life-threatening IFIs by providing a potent, broad-spectrum, and well-tolerated therapeutic that is versatile enough to treat infections from the intensive care unit to the outpatient setting. The results of the ongoing FAST-IC and FORWARD-IM registrational trials are highly anticipated by the infectious disease community and will be pivotal in defining the ultimate role of this groundbreaking agent in the future of medicine.

Works cited

1. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/346372501_Fosmanogepix_A_Review_of_the_First-in-Class_Broad_Spectrum_Agent_for_the_Treatment_of_Invasive_Fungal_Infections
2. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7711534/
3. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/369624597_Safety_and_Pharmacokinetics_of_Intravenous_and_Oral_Fosmanogepix_a_First-in-Class_Antifungal_Agent_in_Healthy_Volunteers
4. Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix - BioSpace, accessed September 29, 2025, https://www.biospace.com/amplyx-announces-positive-top-line-data-in-phase-2-clinical-trial-of-novel-antifungal-fosmanogepix
5. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase - Oxford Academic, accessed September 29, 2025, https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf185/62899496/ciaf185.pdf
6. Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11131969/
7. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections - Semantic Scholar, accessed September 29, 2025, https://pdfs.semanticscholar.org/3ddb/21fdda2cb6d11a096a425b2d7561f3aca5d3.pdf
8. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections - MDPI, accessed September 29, 2025, https://www.mdpi.com/2309-608X/6/4/239
9. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/10.1128/aac.01623-22
10. What is Fosmanogepix used for? - Patsnap Synapse, accessed September 29, 2025, https://synapse.patsnap.com/article/what-is-fosmanogepix-used-for
11. Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/10.1128/aac.01455-23
12. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed September 29, 2025, https://academic.oup.com/jac/article/78/11/2645/7264060
13. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers - PubMed Central, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10112065/
14. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed September 29, 2025, https://academic.oup.com/jac/article/78/10/2471/7246201
15. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/10.1128/aac.01419-22
16. Fosmanogepix - Wikipedia, accessed September 29, 2025, https://en.wikipedia.org/wiki/Fosmanogepix
17. Fosmanogepix: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 29, 2025, https://go.drugbank.com/drugs/DB15183
18. Fosmanogepix | CAS#2091769-17-2 - MedKoo Biosciences, accessed September 29, 2025, https://www.medkoo.com/products/37021
19. Fosmanogepix - TargetMol, accessed September 29, 2025, https://www.targetmol.com/compound/fosmanogepix
20. 2091769-17-2 | Fosmanogepix - ChemScene, accessed September 29, 2025, https://www.chemscene.com/2091769-17-2.html
21. Fosmanogepix (APX001) | Antifungal Agent | MedChemExpress, accessed September 29, 2025, https://www.medchemexpress.com/fosmanogepix.html
22. Fosmanogepix | 2091769-17-2 - Sigma-Aldrich, accessed September 29, 2025, https://www.sigmaaldrich.com/US/en/product/aablocksinc/aabh9a95acd6
23. Fosmanogepix - BioHippo, accessed September 29, 2025, https://www.ebiohippo.com/en/fosmanogepix.html
24. Fast Track designation granted to fosmanogepix for seven indications, accessed September 29, 2025, https://www.europeanpharmaceuticalreview.com/news/99331/fast-track-designantion-granted-fosmanogepix/
25. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS) - Oxford Academic, accessed September 29, 2025, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf185/8109478
26. Pfizer Acquires Amplyx Pharmaceuticals, accessed September 29, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals
27. Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis, accessed September 29, 2025, https://www.basilea.com/news/news?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=1516&type=1546938654&cHash=7af1fce2ad0a11ddb10cb2503b8eb35f
28. Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal - BioSpace, accessed September 29, 2025, https://www.biospace.com/basilea-announces-acquisition-of-fosmanogepix-a-phase-3-ready-broad-spectrum-antifungal
29. Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections, accessed September 29, 2025, https://www.basilea.com/?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=1559&type=1546938654&cHash=dd4db298cc6c7778439d2c5b4636abf9
30. FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications - PR Newswire, accessed September 29, 2025, https://www.prnewswire.com/news-releases/fda-grants-fast-track-status-to-amplyx-pharmaceuticals-for-iv-and-oral-formulations-of-fosmanogepix-apx001-for-seven-different-indications-300913746.html
31. www.europeanpharmaceuticalreview.com, accessed September 29, 2025, https://www.europeanpharmaceuticalreview.com/news/99331/fast-track-designantion-granted-fosmanogepix/#:~:text=These%20indications%20include%20treatment%20of,cryptococcosis%20and%20treatment%20of%20coccidioidomycosis.
32. FDA Grants Fast Track Status to Amplyx Pharmaceuticals for Fosmanogepix, accessed September 29, 2025, https://www.pappas-capital.com/fda-grants-fast-track-status-to-amplyx-pharmaceuticals-for-fosmanogepix/
33. Search Orphan Drug Designations and Approvals - FDA, accessed September 29, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=538616
34. EU/3/22/2644 - orphan designation for treatment of invasive candidiasis | European Medicines Agency (EMA), accessed September 29, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2644
35. Study Details | NCT06433128 | Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT06433128
36. Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/10.1128/aac.01795-20
37. academic.oup.com, accessed September 29, 2025, https://academic.oup.com/jac/article/78/10/2471/7246201#:~:text=The%20prodrug%2C%20fosmanogepix%2C%20is%20rapidly,catalyzes%20inositol%20acylation%20of%20GPI.
38. MGX pharmacokinetic parameters after single and multiple ascending oral FMGX dosesa - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/figure/MGX-pharmacokinetic-parameters-after-single-and-multiple-ascending-oral-FMGX-dosesa_tbl5_369624597
39. Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020) | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/10.1128/aac.01028-22
40. In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/10.1128/aac.01124-20
41. Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/380171950_Fosmanogepix_The_Novel_Anti-Fungal_Agent's_Comprehensive_Review_of_in_Vitro_in_Vivo_and_Current_Insights_From_Advancing_Clinical_Trials
42. Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes, accessed September 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8315997/
43. Fosmanogepix - Semantic Scholar, accessed September 29, 2025, https://pdfs.semanticscholar.org/cff4/33cf59ec6515fa9d945ebe96865a48c218d9.pdf
44. Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Non-neutropenic Rabbits - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/347918654_Efficacy_and_Pharmacokinetics_of_Fosmanogepix_APX001_in_the_Treatment_of_Candida_Endophthalmitis_and_Hematogenous_Meningoencephalitis_in_Non-neutropenic_Rabbits
45. Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits - ASM Journals, accessed September 29, 2025, https://journals.asm.org/doi/pdf/10.1128/aac.01795-20
46. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers - Scite, accessed September 29, 2025, https://scite.ai/reports/safety-and-pharmacokinetics-of-intravenous-MVOLjWDm
47. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia - PubMed, accessed September 29, 2025, https://pubmed.ncbi.nlm.nih.gov/37681450/
48. Fosmanogepix Completed Phase 1 Trials for Fungal Infections Treatment | DrugBank Online, accessed September 29, 2025, https://go.drugbank.com/drugs/DB15183/clinical_trials?conditions=DBCOND0032278&phase=1&purpose=treatment&status=completed
49. Fosmanogepix Completed Phase 1 Trials for Invasive Fungal Infections Basic Science, accessed September 29, 2025, https://go.drugbank.com/drugs/DB15183/clinical_trials?conditions=DBCOND0030131&phase=1&purpose=basic_science&status=completed
50. 1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial - ResearchGate, accessed September 29, 2025, https://www.researchgate.net/publication/348173009_1157_Clinical_Safety_Efficacy_and_Pharmacokinetics_of_Fosmanogepix_a_Novel_First-in-class_Antifungal_in_Patients_with_Renal_Insufficiency_Subset_Analysis_from_a_Phase_2_Candidemia_Trial
51. Invasive Candidiasis Completed Phase 2 Trials for Fosmanogepix (DB15183) - DrugBank, accessed September 29, 2025, https://go.drugbank.com/indications/DBCOND0032522/clinical_trials/DB15183?phase=2&status=completed
52. Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris : results from a Phase 2 trial - UPSpace, accessed September 29, 2025, https://repository.up.ac.za/items/1e04ddca-bcd4-4b50-9a91-c5107367e4a8
53. Invasive Fungal Infections Terminated Phase 2 Trials for Fosmanogepix (DB15183), accessed September 29, 2025, https://go.drugbank.com/indications/DBCOND0030131/clinical_trials/DB15183?phase=2&status=terminated
54. Study Details | NCT05421858 | A Phase 3 Efficacy and Safety Study ..., accessed September 29, 2025, https://clinicaltrials.gov/study/NCT05421858
55. Infectious Diseases UCLA Clinical Trial | A Phase 3 Efficacy and ..., accessed September 29, 2025, https://www.uclahealth.org/clinical-trials/phase-3-efficacy-and-safety-study-fosmanogepix-treatment
56. A Phase 3 Efficacy and Safety Study of Fosmanogepix for the ..., accessed September 29, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05421858/a-phase-3-efficacy-and-safety-study-of-fosmanogepix-for-the-treatment-of-adult-participants-with-candidemia-and-or-invasive-candidiasis
57. A Phase 3 Efficacy and Safety Study of Fosmanogepix for t... - Clinical Trial Discovery, accessed September 29, 2025, https://clinicaltrial.be/fr/details/454689?only_active=0&only_eligible=0&only_recruiting=0&per_page=100
58. NCT05421858 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. | ClinicalTrials.gov, accessed September 29, 2025, https://www.clinicaltrials.gov/study/NCT05421858
59. A Study to Learn About the Study Medicine (Called Fosmanogepix/ PF-07842805) in People With Candidemia and/or Invasive Candidiasis. - Pfizer Clinical Trials, accessed September 29, 2025, https://www.pfizerclinicaltrials.com/find-a-trial/nct05421858-candidemia-trial
60. NCT06925321 | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. | ClinicalTrials.gov, accessed September 29, 2025, https://clinicaltrials.gov/study/NCT06925321
61. News : Basilea, accessed September 29, 2025, https://www.basilea.com/news
62. Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections, accessed September 29, 2025, https://beam-alliance.eu/basilea-initiates-phase-3-study-with-antifungal-fosmanogepix-in-invasive-mold-infections/
63. Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials - Semantic Scholar, accessed September 29, 2025, https://www.semanticscholar.org/paper/Fosmanogepix%3A-The-Novel-Anti-Fungal-Agent%E2%80%99s-Review-Almajid-Bazroon/a3d1299d9e907070e641cb77589701dbfae51647
64. Clinical Study Results - – Thank You –, accessed September 29, 2025, https://www.pfizer.com/sites/default/files/plsr-studies/APX001-202%20(C4791010)%20Plain%20Language%20Study%20Results%20Summary%20(PLSRS)%20Phase%202.pdf